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However, the subject of regenerative medicine/tissue engineering pathology has never received focused attention. Defining and classifying tissue engineering pathology is long overdue. In the next decades, the field of transplantation will enlarge at least tenfold, through a hybrid of tissue engineering combined with existing approaches to lessening the organ shortage. Gradually, transplantation pathologists will become tissue-(re-) engineering pathologists with enhanced skill sets to address concerns involving the use of bioengineered organs. We outline ways of categorizing abnormalities in tissue-engineered organs through traditional light microscopy or other modalities including biomarkers. We propose creating a new Banff classification of tissue engineering pathology to standardize and assess de novo bioengineered solid organs transplantable success in vivo. We recommend constructing a framework for a classification of tissue engineering pathology now with interdisciplinary consensus discussions to further develop and finalize the classification at future Banff Transplant Pathology meetings, in collaboration with the human cell atlas project. A possible nosology of pathologic abnormalities in tissue-engineered organs is suggested.
K E Y W O R D S
bioengineering, biomarker, biopsy, cellular transplantation (non-islet), classification systems:
Banff classification, editorial/personal viewpoint, pathology/histopathology, regenerative medicine, tissue injury and repair, translational research/science 5 and more traditional approaches. 6 If the field of transplantation is to be increased tenfold or more in size to fill the expanding need for organ replacement, regenerative medicine will be the major cause of this improvement, but there will be many other secondary causes in addition. A hybrid of these different modalities working in concert is likely the most appropriate model for the future of transplantation, with tissue engineering/regenerative medicine approaches eventually becoming the dominant approach ( Table 1) .
| INTRODUCTION
The future safety and efficacy of bioengineered tissues and organs is crucial to long-term transplantation success. It cannot be assumed that every rehabilitated or stem cell-generated organ has normal structure and function and will provide net benefit to the patient. Indeed a first branch point in a taxonomy of engineered organs-be they repopulated scaffolds or cells on chips-is distinguishing deviations from a gold standard healthy functioning native organ arising from engineering decisions or problems of generation, versus problems of deterioration in situ. Pathologic examination of organs produced by regenerative medicine/tissue engineering before transplantation and monitoring after transplantation will be crucial to the success of this new medical discipline. Some of this monitoring will be via soluble biomarkers, 7 or possibly employing implantable sensors as well as by more traditional pathology techniques.
In this paper, we define a new pathology discipline, tissue engineering pathology, and propose a basic construct for a new Banff classification of this new discipline, with the aim of having the first full version of the classification finalized through consensus discussions at the 2021, 2023, and 2025 Banff allograft pathology meetings. It will be along organ lines, similar to the current Banff classification scheme [8] [9] [10] but with a focus entirely separate from the current scheme. Since it is likely that the new Tissue
Engineering Pathology classification will overlap with the current Banff classification for at least a decade, it is important that it be constructed in a fashion that will not be confused with the current Transplant Pathology classification, so both classifications can easily be scored simultaneously. Clinical trials of encapsulated islet cells are underway 18 and trials with a bioartificial kidney with silicon filter and human cells are slated to start by the end of 2017. 19 The range of clinically useful bioengineered constructs is very broad and even includes vascular conduits for hemodialysis without cells. techniques to enhance stem cell repair in tissues and xenotransplantation to solve the problem of organ shortage and tissue repair once and for all. These techniques may also hold the promise of reducing or avoiding rejection, since the organs implanted could be made more or less genetically identical to the recipient, or protected from rejection through bio-modification or encapsulation. Extra-corporeal perfusion allowing ex vivo repair and rehabilitation of organs to be transplanted is another aspect of regenerative medicine, as is the production of organoids: simplified organs in miniature created by stem cells or progenitor cells. 21 The number of publications per year in these fields shows that TET is no longer something of the distant future; it is occurring right now with PubMed "regenerative medicine" publication numbers in 2016
| HISTORY AND BACKGROUND
(6216) nearly doubling those in 2013 (3334). A PubMed search on
words like "Decellularized" shows how the field has evolved over the past two decades. Table 2 shows the related regenerative medicine standards that exist, in the areas of scaffolds, bioengineered bone, tendon, and meniscus. Current approved therapies are shown in Table 3 .
| TISSUE ENGINEERING PATHOLOGY (TEP) DEFINED

| TISSUE ENGINEERING PATHOLOGY AND THE 21ST CENTURY CURES ACT
| COMPROMISES-" GOOD ENOUGH PATHOLOGY"
Many abnormalities in bioengineered organs in animals are qualitatively distinct from abnormalities seen in transplanted or native human organs of today. These often include a microvasculature inadequate to support functional parenchymal cells, missing cells, cells in the wrong places, misshapen structures, or structures that appear perfect by light microscopy but do not properly function. 24, 25 As procedural limitations are overcome, these abnormalities in function and pathology will decrease. Until then, these artifacts must be considered part of the disease classification, with the eventual aim of eliminating them. Remuzzi et al. 25 highlight "the major physical barriers that limit in vitro recellularization of acellular kidney scaffolds" (getting enough of the right cells to the right places), "the nonuniform focal cell seeding, and the limited cell proliferation with culture time." We presume these barriers will be overcome in the next six years and then the nascent Banff classification of tissue engineering pathology will change substantially and outlooks overall will improve. The situation is analogous to the situation that existed in transplantation in the beginning when hyperacute rejection was a common threat and immunosuppression was much less effective in controlling acute rejection. 26 In an analogous way, the present barriers to success will be overcome and then the classification project this paper describes will be increasingly needed. 
T A B L E 2 Regenerative medicine standards related to tissue engineering pathology (full references in Supplementary material)
Optimization and Critical Evaluation of Decellularization Strategies to Develop Renal Extracellular Matrix Scaffolds as Biological
| EXAMPLE #1 OF TISSUE ENGINEERING PATHOLOGY, THE DECELLULARIZED RECELLULARIZED RODENT KIDNEY
"We had quite a few kidneys blow up in the jar" Harald Ott says at minute 2:33 of the Nature Medicine video. 24, 27 It never sounded easy, but those bioengineered rat kidneys that survived the seeding procedure and began functioning had a myriad of morphologic abnormalities that helped shape our thinking about a classification of tissue engineering pathology ( Figure 1A,B ). An important insight is looking at the recellurized organ "from a device perspective" and thinking about what specific functions it might serve (course video from minute 9). 28 The work of Remuzzi et al 25 provides considerable additional data on this rat model and suggests that in the first instance the recellularized organ might be better at filtration than other functions since so many of the cells infused seem to end up in the glomerulus. 
| EXAMPLE #2 HUMAN KIDNEY EXTRACELLULAR MATRIX SEEDED WITH AMNIONIC FLUID STEM CELLS
4.
Are there missing structural elements that represent a risk to the patient? (missing long loops of Henle that could cause lethal polyuria through inability to concentrate the urine, absence of a biliary drainage system in the liver) (Figure 3 ).
5.
Is there too much endothelial disruption for the organ to be properly perfused? One cannot assume that all important questions can be answered through routine morphologic examination. Some important questions of stem cell-generated tissue and organ suitability for transplantation may be best answered through biomarkers (see Supplementary Material) 7 or by using genetic analysis, single cell genomics, intravital microscopy, immunofluorescence, or electron microscopy. It is not possible to predict in advance which modalities of examination will prove to be most important clinically in the practice of the new discipline of TEP. Indeed, we will likely be exploring structure-function relationships in a whole new way in regenerative medicine transplantation.
There are some quantitative concepts that are valuable. The kidney contains more than 26 types of cells. 30 In a recent review One might also think practically about a more broadly conceptual initial approach, dividing diseases encountered in tissue-engineered organs into those which can also be found in native and transplanted organs and are in existing classifications, and those pathologies peculiar to the tissue engineered organ. In that latter category, one can divide the changes encountered uniquely in tissue-engineered organs into the following categories, but also distinguishing whether the abnormality arose in construction of the organ or was acquired later:
1. Normal, no abnormalities found 
| THE LARGER CONTEXT: INTEGRATING TET WITH PROJECTS SUCH AS THE HUMAN CELL ATLAS PROJECT AND "LIQUID BIOPSY" CIRCULATING DNA DETECTION
It would be ideal if the tissue engineering pathology classification we create is not something isolated on its own, idiosyncratic, and based mainly on abnormalities seen in rodent models, 24, 25, 27 but fits within a larger human context. A partnership with the newly described human cell atlas project of Aviv Regev and Sarah Teichmann would be highly desirable (see Supplemental Material) 32 as would a partnership with "liquid biopsy" systems for detecting circulating DNA in cancer diagnosis. 33 The HCAP is described as:
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